LANGLEY, BC / ACCESSWIRE / April 30, 2021 / Phyto Extractions Inc. (formerly Adastra Labs Holdings Ltd.) (CSE:XTRX) (FRA:D2EP) ("Phyto Extractions" or the "Company") announces that interim CEO J. Scott
XPhyto Therapeutics Corp.: XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test
VANCOUVER, BC / ACCESSWIRE / March 10, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY / OTCQB:XPHYF / FSE:4XT) ( XPhyto or the Company ), and its exclusive German diagnostics development partner, 3a-diagnostics GmbH ( 3a ), are pleased to announce successful EN ISO 13485 certification for the rapid point-of-care, SARS-CoV-2 RT-PCR Test System ( Covid-ID Lab ). This standardization and quality assurance certification provides authorization for distribution of Covid-ID Lab upon receipt of CE mark (CE-IVD) approval. The Company expects CE-IVD approval as an in vitro diagnostic product in March 2021.
EN ISO 13485 is the internationally recognized European standard for quality control and management systems in the design and manufacture of medical devices. It is accepted as the basis for CE certification of medical devices under relevant European directives and regulations.
XPhyto Therapeutics Corp.: XPhyto Completes Corporate Rebranding and Launches New Website
VANCOUVER, BC / ACCESSWIRE / March 4, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ( XPhyto or the Company ), is pleased to announce that the Company has completed a corporate rebranding and launched a new website which can be viewed at www.xphyto.com.
The rebranding decision reflects the Company s commitment to operational achievement in 2021 as a number of product development programs advance from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting value creation through commercialization of its development pipeline and focused investment in impact driven innovation.
XPhyto Therapeutics Corp.: XPhyto Provides Updated Comments on Promotional and Marketing Activity
XPhyto Therapeutics Corp. (
XPhyto or the
Company ) at the request of IIROC and the Canadian Securities Exchange (the
CSE ) is providing additional comments to its news release and list of third-party providers dated January 22, 2021 with regards to recent promotional and investor relations activity (
Promotional Activity ) provided by said third-parties, in particular a newsletter published by WallStreetAlerts, on behalf of the Company.
The Company reminds investors that the best source for full disclosure about the company is the company itself, SEDAR or CSE profile pages for regulatory filings and news releases. The Company acknowledges that prior to the date of this news release, XPhyto did not comply with the CSE requirements to complete and post Form 10 Notices of Proposed Significant Transactions disclosing its contracts with the third-party providers. The Company has